Who are Evommune, Inc.'s main suppliers?

Evommune, Inc. (EVMN) key suppliers include: DERMIRA-INC, APRILBIO-CO-LTD, DERMIRA. View the full supplier network at chainsifter.com/chain/EVMN.

Who are Evommune, Inc.'s major customers?

Evommune, Inc. (EVMN) key customers include: MARUHO-CO-LTD, EMERGING-GROWTH-COMPANY. View the full customer network at chainsifter.com/chain/EVMN.

What sector is Evommune, Inc. in?

Evommune, Inc. (EVMN) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Evommune, Inc. Supplier List (EVMN): 3 Verified Suppliers

3Suppliers

2Customers

2Debt Items

0Related Chains

Source-Backed Evidence Depth

Evommune, Inc. (EVMN) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

8Total relationships

2Distinct source URLs

7High confidence

0.846Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Evommune, Inc. Suppliers

Ticker	Name	Confidence	Evidence
DERMIRA-INC	DERMIRA-INC	90%	In consideration for the licenses granted to us under the Dermira License Agreement, we paid to Dermira a $7.5 million upfront license fee.
APRILBIO-CO-LTD	APRILBIO-CO-LTD	85%	AprilBio granted the Company an exclusive worldwide license to develop and commercialize an IL-18BP compound ("EVO301").
DERMIRA	DERMIRA	80%	we obtained an exclusive, worldwide license to develop and commercialize certain compounds, including EVO756.

Evommune, Inc. Customers

Ticker	Name	Confidence	Evidence
MARUHO-CO-LTD	MARUHO-CO-LTD	90%	The Company recognized $ 3.0 million in license revenue for the three months ended March 31, 2025 upon the satisfaction of the performance obligation.
EMERGING-GROWTH-COMPANY	EMERGING-GROWTH-COMPANY	62%	hen expensed as the related goods are delivered or the services are performed. Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of t…

Evommune, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
EVMN-DEBT-14225	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2025-12-31.
EVMN-DEBT	Debt stack $9.1M	90%	Market cache reports total debt of $9.1M.

Evommune, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Evommune, Inc..

Evommune, Inc. Ownership

Holder	Name	Confidence	Evidence
EVMN-OWNER-EQT-FUND-MANAGEMENT-S-A-R-L	EQT Fund Management S.a r.l.	90%	13F overlay lists EQT Fund Management S.a r.l. as top holder; 84 tracked holders.

Evommune, Inc. Extended Supply Chain Network

No secondary connectionsNo correlated companies found through shared supply chain relationships.

Evommune, Inc. Supply Chain